

Current Clinical Practice
Series Editor: Tommy Koonce

Paul Lyons
Nathan McLaughlin

Obstetrics in Family Medicine

A Practical Guide

Third Edition

 Humana Press

Current Clinical Practice

Series Editor

Tommy Koonce
Family Medicine
University of North Carolina at Chapel Hill
Chapel Hill, USA

More information about this series at <http://www.springer.com/series/7633>

Paul Lyons • Nathan McLaughlin

Obstetrics in Family Medicine

A Practical Guide

Third Edition

 Humana Press

Paul Lyons
School of Medicine
California University of Science
and Medicine
San Bernardino, CA
USA

Nathan McLaughlin
School of Medicine
University of California
Riverside, CA
USA

Current Clinical Practice

ISBN 978-3-030-39887-3

ISBN 978-3-030-39888-0 (eBook)

<https://doi.org/10.1007/978-3-030-39888-0>

© Springer Nature Switzerland AG 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Humana imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

One of the joys of working in obstetrics is the privilege of being present as the current generation gives rise to the next generation. It is, of course, not the transition in its entirety, but it is a seminal moment in the journey. Over the years, I have been blessed to be present with thousands of women and their families at precisely that moment, to share in that journey and all its associated emotions—hope, fear, anxiety, disappointment (on occasion), and joy.

When I wrote the first edition of this textbook, I was in the midst of that journey in my own life with a young career and an even younger family. With this third edition, my children are now grown, my professional life has evolved, and I am pleased to both recognize and acknowledge those changes. I am grateful to my wife, Cynthia, who continues to provide support and inspiration, and to my two children, Devin and Dylan, now delightful young adults, who give me great hope for and faith in the next generation.

With this edition I am pleased to share in generational change, in the professional sense as well. As my professional life has less direct involvement in delivery of obstetrical patient care, I have become in some ways the audience for as much as the author of this text, “all of us who care for women may find it useful to have a reference that addresses key clinical issues in this important element of women’s health,” as I noted in the preface to the second edition. In that transition, I have been blessed to be present with young professionals who represent the future such care. I am pleased to share the creation of this edition with Dr. Nathan McLaughlin, a delightful young physician who gives me great hope for and faith in what comes next.

San Bernardino, CA, USA

Paul Lyons

Preface

Having great mentorship is instrumental to success and can greatly affect one's trajectory in life. I am lucky to have had a sizeable number of influential mentors that have shaped my education and career. In medical school, it was Dr. Michelle Whitehurst-Cook and Dr. Steve Crossman providing shining examples of what family physicians could be. During residency training Dr. Evelyn Figueroa and Dr. Mark Potter were there to guide me into full-spectrum family medicine including obstetrics, which has enriched my life greatly. I am indebted to those listed above and countless others who have helped to bring me to where I am today.

Over the past 6 years, Dr. Paul Lyons has provided me with mentorship, support, guidance, and opportunity that I could only dream of. The most recent opportunity was in the form of this book. Being asked to help write this third edition of *Obstetrics in Family Medicine: A Practical Guide* is a great honor, and honestly one that I never expected. Dr. Lyons' casual belief in me bolstered my confidence to take on a task that was beyond anything I had done before. Despite his constant assertions that he really doesn't do anything, his impact on me has been immense. I can only hope to provide others with the guidance and support that my mentors have given to me, for without that support I truly would not be where I am today.

Most importantly, I would like to thank my loving wife, Whitney Sullivan-Lewis, MD, for providing me with endless support and reassurance that allow me to have a fulfilling life and career. She is an amazing doctor, wife, and mother, and I should tell her this more often than I do. Lastly, all of my love and affection to my two daughters, Virginia and Josephine, who love me, despite my imperfections, and serve as a constant reminder of what is truly important in life.

Riverside, CA, USA

Nathan McLaughlin

Contents

Part I Preconception and Prenatal Care

1	Physiology	3
	Background	3
	Physiology of Menstruation	4
	Physiology of Fertility	5
	Hypothalamic Function	5
	Pituitary Function	6
	Ovulation	6
	Physiology of Pregnancy	7
	Cardiovascular Changes	8
	Renal/Urinary Changes	8
	Gastrointestinal Changes	9
	Hematological Changes	9
2	Preconception Counseling	11
	Background	11
	The Patient	12
	The Environment	13
	Getting Started	13
	Screening	14
	Education	15
	Intervention	16
3	Prenatal Care	19
	Background	20
	Key Domains of Prenatal Information	21
	Frequency of Prenatal Visits	22
	The First Prenatal Visit	22
	History	22
	Physical Examination	25
	Laboratory and Diagnostic Testing	25

Estimating Gestational Age	26
Laboratory Testing	27
Treatment and Follow-Up	27
Follow-Up Prenatal Visits	27
Interval History and Physical Exam	28
Structure of Prenatal Visits	28
Interval Laboratory and Diagnostic Studies	29
4 Medications in Pregnancy	31
Background	32
General Principles of Medication Use in Pregnancy	32
Chronic Medical Conditions	32
Acute Medical Conditions	33
Acute Obstetrical Conditions	34
Therapeutic Categories and Considerations	34
Proven Human Teratogens	35
Special Considerations	36
Tobacco	36
Alcohol	37
Illicit Drugs	37
Over-the-Counter Medications	37
OTC Pain Medications	38
Acetaminophen	38
Aspirin	38
Nonsteroidal Anti-inflammatory Drugs	39
OTC Cough/Cold/Allergy Medications	39
Antihistamines	39
Decongestants	39
Cough Medications	40
5 Vaccines in Pregnancy	41
Background	41
Infectious Diseases in Pregnancy	42
Vaccines Recommended in All Pregnancies	42
Influenza	42
Tetanus, Diphtheria, and Pertussis (Tdap)	43
Vaccines to Be Considered Based on Risk vs. Benefit	43
Hepatitis A	43
Yellow Fever	43
Meningococcal (B)	43
Vaccines for Use if Indicated	44
Vaccines Contraindicated in Pregnancy	44

Part II Complications in Pregnancy

- 6 Dysmorphic Growth and Genetic Abnormalities** 47
 - Background 47
 - History 48
 - Physical Examination 49
 - Diagnosis 49
 - Obstetrical Screening Tests 50
 - What Is Measured 50
 - What Is Detected 50
 - Confirmation/Follow-Up 51
 - Amniocentesis 51
 - Chorionic Villus Sampling 52

- 7 Intrauterine Growth Restriction** 53
 - Background 53
 - Risk Factors 55
 - Fetal–Genetic Factors 55
 - Uterine–Environmental Factors 55
 - Maternal Factors 56
 - Toxic Exposures 56
 - Constitutional Factors 57
 - Complications of Growth Restriction 57
 - Antenatal Tracking and Diagnosis 57
 - Screening for Risks 59
 - Diagnosis 60
 - Management 60
 - Risk Reduction 60

- 8 Preterm Labor** 63
 - Background 64
 - Factors Associated with Preterm Labor 64
 - Preconception Factor 65
 - Environmental Factors 65
 - Patient-Related Factors 65
 - Postconception Factors 65
 - Diagnosis 66
 - Intake Assessment 66
 - History 66
 - Physical Examination 67
 - Laboratory Studies 67

Management	67
Management Prior to 34 Weeks' Gestation	69
Management at 34–37 Weeks	70
Assessment of Fetal Lung Maturity	70
Lecithin-to-Sphingomyelin Ratio	71
Phosphatidylglycerol	71
Additional Tests	71
9 Premature Rupture of Membranes	73
Background	73
Diagnosis	74
History	74
Physical Examination	75
Laboratory	76
Management	77
Management at Term	78
Preterm Management	78
10 Early Pregnancy Bleeding	79
Background	80
General Approach to Early Pregnancy Bleeding Per Vagina	80
History	81
Physical Examination	81
Ultrasound	83
Laboratory Studies	83
Ectopic Pregnancy	84
Background	84
Diagnosis	84
Management	85
Spontaneous Abortion	86
Background	86
Diagnosis	87
Management	88
11 Late-Pregnancy Bleeding	91
Background	92
General Approach to Late-Pregnancy Bleeding Per Vagina	92
History	94
Ultrasound	94
Physical Examination	95
Laboratory Studies	95
Placenta Previa	95
Background	95
History	96
Ultrasound Examination	96
Physical Examination	96

Laboratory Studies	96
Management	97
Management at Term	97
Preterm Management	97
Abruptio Placenta	97
Background	97
History	98
Ultrasound	98
Physical Examination	98
Laboratory Studies	99
Management	99
12 Recurrent Pregnancy Loss	101
Background	101
Diagnosis	103
Management	103
History	103
Physical Examination	104
Diagnostic Studies	104
13 Rh Isoimmunization	107
Background	107
Fetal Consequences of Isoimmunization	108
Newborn Consequences of Isoimmunization	109
Diagnosis	109
History	109
Physical Examination	109
Diagnostic Studies	109
Management Prior to Isoimmunization	110
Management of Pregnancies with Rh-Sensitized Mothers	110
Amniotic Fluid Assessment	112
Ultrasonography	112
Percutaneous Umbilical Blood Sampling	112
14 Infection in Pregnancy	113
Background	114
Symptoms of Infection in Pregnancy	115
Maternal Infection	115
Fetal Infection	116
Antibiotic Use in Pregnancy	117
Sulfonamides	117
Fluoroquinolones	118
Aminoglycosides	118
Vaginitis/Vaginosis	118
Background	118
History	119

Physical Examination	119
Laboratory Studies	119
pH <i>Testing</i>	120
KOH <i>Whiff</i>	120
Microscopic Examination	120
Treatment	120
Bacterial Vaginosis	120
Trichomoniasis	121
Yeast Vaginitis	121
Gonorrhea/Chlamydia	121
Urinary Tract Infections	122
Background	122
Diagnosis	122
History	122
Physical Examination	123
Laboratory Examination	123
Treatment	123
Group B Strep	124
Background	124
Diagnosis	124
Universal Screening	125
Treatment	125
15 Hypertension in Pregnancy	127
Background	128
Diagnosis	128
Diagnostic Criteria	128
History	130
Physical Examination	130
Laboratory Studies	130
Management	131
Chronic Hypertension	131
Pre-eclampsia	131
Prevention	131
Management	131
Seizure Prevention	133
Postpartum Management	134
16 Diabetes in Pregnancy	135
Background	135
Diagnosis	136
Pregestational Diabetes	137
Management	137
Management in Pregnancy	138
Diet	138
Insulin	139

- Oral Hypoglycemics 139
- Blood Sugar Monitoring 139
- Gestational Diabetes 140
 - Preconception Management 140
 - Management in Pregnancy 140
 - Management in Labor 141
 - Postpartum Management 141
- 17 HIV in Pregnancy 143**
 - Preconception Counseling 144
 - Initial Pregnancy Evaluation 144
 - Antiretroviral Use in Pregnancy 145
 - Intrapartum Management 146
 - Postpartum Management 147
- 18 Multigestational Pregnancy 149**
 - Background 149
 - Diagnosis 151
 - History 152
 - Physical Examination 152
 - Laboratory and Diagnostic Studies 152
 - Management 152
 - Prenatal Care 152
 - Labor and Delivery 153
- 19 Postdates Pregnancy 155**
 - Background 155
 - Diagnosis 156
 - History 156
 - Physical Examination 157
 - Diagnostic Studies 157
 - Management 157
 - Assessment of Fetal Well-Being 157
 - Fetal Kick Count 158
 - Amniotic Fluid Volume 159
 - Ultrasound Estimate of Fetal Weight 159
 - Nonstress Test 159
 - Contraction Stress Test 159
 - Biophysical Profile 160

Part III Labor and Delivery

- 20 Normal Labor 163**
 - Background 163
 - Prelabor 164
 - Labor 164
 - Assessment 165

History	165
Physical Examination	165
Dilation	166
Effacement	166
Station	166
Presentation	166
Laboratory Studies	167
Management	167
21 Induction and Augmentation	169
Background	169
Preparation	169
Pharmacological Options	170
Mechanical Options	171
Induction	171
22 Pain Management in Labor	173
Background	173
Nonpharmacological Management	174
Pharmacological Management	174
Narcotic Analgesia	174
Local Anesthesia	175
Epidural–Spinal Anesthesia	175
 Part IV Complications of Labor and Delivery	
23 Assisted Delivery	179
Background	179
Forceps Delivery	180
Use of Forceps	181
Vacuum-Assisted Delivery	181
Cesarean Section	182
24 Prolonged Labor	183
Background	183
Complications of Labor	184
Prolonged Latent-Phase Labor	184
History	185
Physical Examination	185
Laboratory/Diagnostic Studies	185
Management	185
Failure to Dilate/Efface	186
History	186
Physical Examination	186
Laboratory/Diagnostic Studies	187
Management	187
Failure to Descend	188

25	Shoulder Dystocia	189
	Background	189
	Diagnosis	190
	Management	191
26	Malpresentation	193
	Background	193
	Occiput Positions	194
	Diagnosis	194
	Management	194
	Nonoccipital Presentations	194
	Breech Presentation	195
	Compound Presentation	196
27	Fetal Heart Rate Monitoring	197
	Background	197
	Normal Fetal Heart Tracings	198
	Evaluation of Fetal Heart Rate Baseline	198
	Tachycardia	199
	Bradycardia	199
	Evaluation of Fetal Heart Rate Variability	199
	Acceleration	199
	Early Deceleration	200
	Variable Deceleration	200
	Late Decelerations	200
	Classification of Electronic Fetal Monitoring	201
28	Maternal Fever in Labor	203
	Background	203
	Diagnosis	204
	History	204
	Physical Examination	204
	Diagnostic Studies	205
	Management	205
29	Postpartum Hemorrhage	207
	Background	208
	Complications Causing Hemorrhage	208
	Uterine Atony	208
	Lacerations	209
	Retained Placenta	209
	Coagulopathy	209
	Uterine Inversion	209
	Diagnosis	209
	Management	210
	Laceration	210
	Persistent Bleeding	211

30 Perineal Laceration and Episiotomy 213

 Episiotomy 213

 Background 213

 Procedure 214

 Perineal Laceration 214

 Background 214

 Diagnosis 214

 History 214

 Physical Examination 215

 Management 215

Part V Postpartum Management

31 Newborn Evaluation 219

 Background 220

 The Examination 220

 History 220

 Physical Examination 220

 Vital Signs 220

 General Observation 221

 Head and Neck 221

 Eyes 221

 Cardiovascular 221

 Pulmonary/Thoracic 222

 Abdomen 222

 Genital Examination 222

 Anus 222

 Spine 222

 Skin 223

 Extremities 223

 Neurologic 223

 Laboratory and Diagnostic Studies 223

 Vaccination 224

32 Routine Hospital Postpartum Management 225

 Background 225

 Postpartum Day 1 226

 History 226

 Physical Examination 226

 Laboratory Studies 227

 Management 227

 Postpartum Day 2 228

 History 228

 Physical Examination 228

- Laboratory Studies 229
- Management 229
- 33 Complications of the Hospital Postpartum Period 231**
 - Background 231
 - Persistent Postpartum Hemorrhage 231
 - Hypertension 232
 - Thromboembolic Disease 232
 - Fever 232
 - Infection 233
 - Endometritis 233
 - Urinary Tract Infections 234
- 34 Postpartum Clinic Visit 235**
 - Background 235
 - Postpartum Depression 236
 - Infant Care and Feeding 236
 - Sexuality/Relationships 237
 - Vaginal Bleeding 237
 - Self-Care 237
 - Management of Complications 238
 - Hypertensive Disorders 238
 - Gestational Diabetes 238
- Index 239**

Part I
Preconception and Prenatal Care

Chapter 1

Physiology



Contents

Background.....	3
Physiology of Menstruation.....	4
Physiology of Fertility.....	5
Hypothalamic Function.....	5
Pituitary Function.....	6
Ovulation.....	6
Physiology of Pregnancy.....	7
Cardiovascular Changes.....	8
Renal/Urinary Changes.....	8
Gastrointestinal Changes.....	9
Hematological Changes.....	9

Key Points

1. The menstrual cycle can be considered a comprehensive physiological adaptation for potential pregnancy.
2. Normal menstrual cycles last 21–45 days (average 28 days), counted from the first day of menstrual bleeding.
3. Physiological adaptations of pregnancy affect most major organ systems including cardiac, renal, gastrointestinal, and endocrine systems.

Background

Although most patients will not present to their providers with questions concerning the specifics of reproductive physiology, the care and management of pregnant patients begin with an understanding of the physiological environment in which pregnancy occurs (or in some instances, does not occur). Many women’s health providers will face questions concerning menstrual function prior to caring for a

patient's obstetrical needs. Conversely, routine gynecological care may provide an opportunity to begin discussions of pregnancy planning and preconception counseling. For many women, a "routine" gynecological examination is the primary point of contact with the health-care system early in life. For this reason, all providers who care for women should have some understanding of normal reproductive physiological function. A brief overview of menstruation, fertility, and pregnancy follows.

Physiology of Menstruation

Menstruation represents the cyclical physiological preparation for potential pregnancy, followed by removal of endometrial contents if pregnancy does not occur. Most women of reproductive age are familiar with menstruation. The average age of menarche in the United States is approximately 11.5 years. Most menstrual cycles are anovulatory in the first year following menarche and may remain irregularly ovulatory for up to 3 years (although women and providers should be aware that ovulation and/or pregnancy may occur). For the next three to four decades, most women will menstruate every 21–35 days (average 28 ± 7 days). Bleeding is variable but generally lasts 3–5 days (1–7 days may be considered normal) and is of variable intensity (but generally less than 3 oz or 90 cm³).

Although generally considered an ovarian and uterine phenomenon, the normal menstrual cycle may be considered as a comprehensive physiological adaptation in preparation for possible pregnancy. In addition to the uterine and ovarian changes described here, changes can be noted in the cervix, vagina, breast, and core body temperature. The cervical mucus becomes thinner with increased pH to facilitate entry of sperm. Vaginal epithelial cells also undergo change. Mammary ducts proliferate under estrogen and progesterone stimulation, which may lead to breast swelling and tenderness. A small spike in basal body temperature can be seen at the time of ovulation. This observation has contributed to the use of basal body monitoring in fertility management.

Physiologically, bleeding represents the end of one cycle. From the perspective of the patient and the provider, however, bleeding is the most easily identified aspect of the menstrual cycle and is, therefore, used to mark the beginning of each cycle. The first day of menstrual bleeding is day 1 with each day numbered sequentially through the last day prior to the recurrence of bleeding. Each menstrual cycle can be divided into two-halves that differ in hormonal and physiological events. In a typical or average menstrual cycle, each half is approximately 14 days in duration.

The first half of each menstrual cycle is marked by endometrial proliferation and follicular development. In the first week of each menstrual cycle, multiple follicles enlarge. At approximately 1 week, a single follicle becomes dominant and the others involute, becoming atretic. The dominant follicle will, with appropriate hormonal regulation, continue to develop and will eventually rupture releasing an ovum for possible fertilization. With release of the ovum on day 14, the follicle undergoes a series of stereotypic changes filling with blood, granulose, and thecal cell prolif-

eration and displacement of blood by luteal cells (corpus luteum). The luteal cells produce progesterone, which serves to stabilize the thickened endometrium through the second half of the menstrual cycle. The period of follicle development is referred to as the follicular phase. The period of luteal production of progesterone is referred to as the luteal phase.

Follicular development in the first half of each menstrual cycle is marked by follicular production of estrogen and endometrial proliferation in anticipation of possible implantation of a fertilized ovum. This generally occurs late in the first week and throughout the second week of the menstrual cycle. The first half of the menstrual cycle is, for this reason, sometimes referred to as the proliferative phase. With ovulation and luteal production of estrogen and progesterone, uterine glands become active, secreting clear fluid. This phase is referred to as the secretory phase. The endometrium will remain stable and secretory for as long as the progesterone stimulation continues.

If fertilization fails to occur, the corpus luteum will lose function beginning in the second half of the fourth week (corpus albicans). With the loss of hormonal support, endometrial thinning and localized necrosis lead to sloughing of the proliferative portion of the endometrial lining and the onset of menses. Until menopause, this cycle will repeat more or less regularly each month.

Physiology of Fertility

The hormonal changes just described relate to preparation for release of the ovum and subsequent fertilization by sperm. As noted, however, these menstrual changes may occur in the absence of ovulation. In addition, under normal physiological conditions, pregnancy requires the presence of functional sperm in sufficient quantity to ensure fertilization of the released ovum.

In women, the release of an ovum is under the control of the hypothalamic–pituitary–ovarian endocrinological axis. Each of these components must function normally to ensure ovum release. Two pituitary hormones, in particular, are critical to normal ovulatory cycles—follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Hypothalamic Function

Release of pituitary hormones depends on hypothalamic stimulation. The hypothalamus is responsible for stimulation of a variety of pituitary hormones, and hypothalamic dysfunction may manifest with altered fertility or a variety of other endocrinological signs or symptoms. In addition to pituitary stimulation, the hypothalamus is responsible for direct release of oxytocin (of import at the time of labor).

In relation to fertility, hypothalamic release of gonadotropin-releasing hormone (GnRH) stimulates the anterior pituitary production of FSH and LH. GnRH is produced in the hypothalamus and released directly to the pituitary via local blood vessels. Release of GnRH is episodic in brief, timed bursts. Although GnRH cannot be measured directly, pulsatile GnRH release results in pulsatile release of LH which can be measured providing indirect evidence of hypothalamic function. Failure to maintain this episodic release will inhibit pituitary stimulation, probably secondary to downregulation of pituitary receptors. Disruption of the timing of the episodic release will also impair fertility by disrupting the appropriate timing of FSH and LH stimulation of the ovary. In addition, appropriately episodic and timed GnRH stimulates pituitary GnRH receptors enhancing sensitivity at mid-cycle and facilitating a surge in LH at the time of ovulation.

Pituitary Function

As with the hypothalamus, the pituitary is responsible for the release of several hormones regulating a variety of physiological functions. In relation to fertility, the two key hormones are the gonadotropins, FSH and LH. These two agents are released cyclically and in a pulsatile fashion in response to GnRH stimulation. Together they are responsible for regulation of ovarian hormonal secretion. Pituitary release of FSH and LH is also regulated by ovarian hormone release. Ovarian release of estradiol results in negative feedback (inhibition) of FSH release and positive feedback (stimulation) of LH release.

FSH, as the name implies, is responsible for stimulating early follicle development within the ovary. LH fosters ovarian production of estrogen and progesterone from the corpus luteum. In conjunction with LH, FSH is also responsible for terminal maturation. At the point of maturation, a surge in LH levels precipitates follicular rupture and ovum release.

Ovulation

Early in the menstrual cycle, FSH levels are slightly elevated (stimulating follicular development), and LH levels are low. In this phase of the menstrual cycle, estrogen serves an inhibitory role on LH. GnRH stimulation of the pituitary continues, and the sensitivity of the pituitary is enhanced. Approximately 2 days prior to ovulation, the estrogen inhibition is reversed, becoming stimulatory, and a positive feedback loop is established. Approximately 8–10 h prior to ovulation, LH levels reach a peak

(LH surge). Ovulation then occurs. Following ovulation, estrogen once again becomes inhibitory and, in conjunction with elevated progesterone levels, serves to inhibit LH and FSH levels in the second half of the menstrual cycle.

Physiology of Pregnancy

The physiological changes associated with pregnancy are numerous, and the full scope of such changes is beyond the scope of this text. Common physiological changes with pregnancy are summarized in Table 1.1. Recognition of normal physiological changes

Table 1.1 Physiological changes of pregnancy

Cardiovascular
Cardiac enlargement
Increased cardiac output
Systolic flow murmur
Decreased venous return
Decreased peripheral vascular resistance
Decreased blood pressure
Increased blood flow to the uterus, kidneys, skin, breasts
Renal/urinary
Increased urinary stasis
Increased urinary system volume
Kidney enlargement
Renal pelvis dilatation
Ureteral elongation
Increased bladder capacity
Increased glomerular filtration rate
Elevation of renin, aldosterone, angiotensin
Glucosuria
Gastrointestinal
Early satiety
Nausea, vomiting
Constipation
Gingival hypertrophy
Progression of periodontal disease
Decreased gastric emptying
Relaxation of lower esophageal sphincter
Hematological
Increased red blood cell volume
Anemia
Leukocytosis

is necessary not only to understand normal function while pregnant but also to facilitate recognition of physiological abnormalities that lie outside the normal range.

Cardiovascular Changes

Pregnancy can be considered an adaptive high-volume, hyperdynamic cardiovascular state. Increased volume, a newly developed peripheral vascular bed, and anatomic changes associated with an enlarging uterus all serve to alter normal cardiovascular status. The heart, itself, enlarges, and cardiac output increases by nearly 50%. This increased output is initially facilitated by an increase in cardiac volume and subsequently by an increase in heart rate. The increase in output reaches a peak near the end of the second trimester and then remains stable until the end of pregnancy.

The increase in volume may lead to increased flow turbulence within the heart. This turbulence may be apparent clinically as a systolic ejection murmur. Such a murmur will manifest in 80–90% of all pregnant women. This murmur is a normal physiological finding and does not warrant further cardiovascular investigation.

Vascular changes are also common in pregnancy. With an increase in uterine size, venous return via the inferior vena cava may be directly impaired. Placing the patient in the left lateral recumbent position may alleviate the direct pressure of the uterus on the vena cava and facilitate enhanced venous return. The direct compression of venous return from the lower extremities may lead to peripheral edema. Peripheral vascular resistance declines with pregnancy as maternal cardiac output increases. Compensatory venous response to rapid position changes may also be impaired in pregnancy causing light-headedness or dizziness with rapid positional changes. Blood pressure often declines slightly (approximately 10 mmHg diastolic) with a nadir in the second trimester and a slight rise (to near prepregnant levels) near the end of pregnancy.

Blood flow is altered in pregnancy as well. The most obvious change is the increase in uterine blood flow with the development of the uteroplacental vascular bed. Blood flow through this vascular bed is facilitated by vascular resistance that is low relative to the overall peripheral vascular resistance. In addition to increased blood flow to the uterus, maternal blood flow is increased to the kidneys, breast, and extremities (including increased flow to the skin). Although concern has been raised that exercise may divert blood flow from these key areas to muscles, this has generally not been found to be clinically significant except for women who significantly increase their activity level from their prepregnancy baseline. A reasonable recommendation would be that women may continue exercise through pregnancy at a level not to exceed their usual degree of exertion.

Renal/Urinary Changes

Pregnancy is marked by an increase in urinary stasis. The direct impingement of the uterus and fetus on the bladder contributes to this effect as do anatomic changes within the urinary tract. Kidneys enlarge, the renal pelvis dilates, and the course of